Table 1 Characteristics of septic patients at baseline stratified by 30-day survival (n = 135).
From: DNA methylation of a NF-κB binding site in the aquaporin 5 promoter impacts on mortality in sepsis
Total cohort | Sepsis survivors | Sepsis non-survivors | p-value | |
|---|---|---|---|---|
n = 135 | n = 88 | n = 47 | ||
Characteristics | ||||
Age [years]* | 57.5 (±16.0) | 57.9 (±15.9) | 56.9 (±16.0) | 0.757 |
Sex, male n (%) | 78 (57.8%) | 50 (56.8%) | 28 (59.6%) | 0.855 |
Height [cm]* | 170 (±12) | 171 (±12) | 170 (±12) | 0.728 |
Weight [kg]* | 80.7 (±21.5) | 82.6 (±20.7) | 77.2 (±22.8) | 0.239 |
Body mass index [kg/m2]* | 27.2 (±5.5) | 27.8 (±5.3) | 26.0 (±5.9) | 0.128 |
SAPS II score* | 41.8 (±18.0) | 39.4 (±19.2) | 44.6 (±15.9) | 0.119 |
SOFA score* | 11.4 (±5.1) | 10.6 (±5.7) | 12.9 (±3.4) | 0.003 |
Procalcitonin concentration [ng/ml]# | 3.2 (0.9–12.6) | 2.8 (0.9–8.1) | 3.8 (1.0–18.1) | 0.386 |
C-reactive protein concentration [mg/dl]# | 12.4 (5.7–20.5) | 12.6 (5.3–20.5) | 12.1 (6.1–19.6) | 0.723 |
Leukocyte concentration [nl−1]# | 12.8 (9.0–19.3) | 12.6 (9.2–18.2) | 16.2 (8.1–20.2) | 0.652 |
Creatinine concentration [mg/mL]# | 1.6 (1.0–2.2) | 1.5 (0.9–2.0) | 1.8 (1.1–2.6) | 0.101 |
Platelet count [nl−1]# | 112 (60–227) | 143 (81–235) | 95 (52–168) | 0.025 |
Total bilirubin concentration [mg/dL]# | 1.1 (0.5–2.6) | 0.9 (0.4–2.0) | 1.4 (0.8–3.5) | 0.011 |
Continuous haemofiltration/dialysis, n (%) | 57 (42.2%) | 33 (37.5%) | 24 (51,0%) | 0.129 |
Mechanical ventilation, n (%) | 74 (54.8%) | 39 (44.3%) | 35 (79.5%) | 0.001 |
Blood cultures, n (%) | 0.581 | |||
Gram-positive isolates | 30 (22.2%) | 18 (20.5%) | 12 (25.6%) | |
Gram-negative isolates | 38 (28.1%) | 23 (26.1%) | 15 (31.9%) | |
Fungal isolates | 6 (4.5%) | 3 (3.4%) | 3 (6.4%) | |
Mixed isolates | 22 (16.3%) | 15 (17.0%) | 7 (14.9%) | |
Negative blood cultures | 39 (28.9%) | 29 (33.0%) | 10 (21.3%) | |
Site of infection, n (%) | 0.446 | |||
Pneumonia | 49 (36.3%) | 34 (38.6%) | 15 (31.9%) | |
Urinary tract infection | 31 (23.0%) | 22 (25.0%) | 9 (19.1%) | |
Abdominal infection | 14 (10.4%) | 6 (6.8%) | 8 (17.0%) | |
Skin or muscle infection | 6 (4.4%) | 3 (3.4%) | 3 (6.4%) | |
Line infection | 10 (7.4%) | 6 (6.8%) | 4 (8.5%) | |
Other/unknown origin | 25 (18.5%) | 17 (19.4%) | 8 (17.1%) | |
Medical history, n (%) | 0.969 | |||
Cardiovascular disease | 35 (25.9%) | 23 (26.1%) | 12 (25.5%) | |
Haemato-oncologic disease | 7 (5.2%) | 3 (3.4%) | 4 (8.5%) | |
Gastrointestinal disease | 34 (25.2%) | 24 (27.3%) | 10 (21.3%) | |
Gastrointestinal cancer | 16 (11.8%) | 10 (11.4%) | 6 (12.8%) | |
Lung disease | 22 (16.3%) | 15 (17.0%) | 7 (14.9%) | |
Lung cancer | 5 (3.7%) | 2 (2.3%) | 3 (6.4%) | |
Urogenital disease | 7 (5.2%) | 5 (5.7%) | 2 (4.3%) | |
Urogenital cancer | 5 (3.7%) | 4 (4.5%) | 1 (2.1%) | |
Trauma | 4 (3.0%) | 2 (2.3%) | 2 (4.3%) | |
